Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNEQ Sorrento Therapeutics Inc
SPI SPI Energy Co Ltd
AMC AMC Entertainment Holdings Inc
BOF BranchOut Food Inc
KITT Nauticus Robotics Inc
EAT Brinker International Inc
JCSE JE Cleantech Holdings Ltd
GVP GSE Systems Inc
CURV Torrid Holdings Inc
APRN Blue Apron Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

Closing Price
Day's Change
-0.0062 (-6.19%)
B/A Size
Day's High
Day's Low
(Below Average)

10-day average volume:

Canopy Growth stock soars on heavy volume again, amid cannabis investor optimism over possible favorable legislation

3:36 pm ET September 8, 2023 (MarketWatch)

Shares of Canopy Growth Corp. (WEED.T) shot up 21.7% toward a near four-month high in very active afternoon trading, putting them on track for the fifth double-digit percentage gain in seven sessions. The stock has rocketed 130% over the past seven session. Trading volume was 107.7 million shares as of Friday afternoon, to mark the fourth 100+-million-share volume day in the past six sessions, while the average volume over the past 30 days was about 36.3 million shares. The stock's surge comes as Senate Banking Committee chair Sherrod Brown said Wednesday that there is "an agreement imminent" on the SAFE Banking Act, according to a Politico report, which could make it easier for the financial industry to work with cannabis companies. Among other cannabis stocks, shares of Tilray Brands Inc. (TLRY) gained 2.4%, of Cronos Group Inc. climbed 6.0% and of Aurora Cannabis Inc. (ACB.T) jumped 12.5%. The AdvisorShares Pure US Cannabis ETF (MSOS) rose 7.5% on volume of 13.9 million shares, compared with the full-day average of about 5.6 million shares, while the S&P 500 slipped 0.1%. The cannabis ETF has soared 77% over the past seven sessions.

-Tomi Kilgore

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.


(END) Dow Jones Newswires

September 08, 2023 15:36 ET (19:36 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.